You are here

Article Text

Article menu
Download PDFPDF
Treatment
Review: weight-reducing agents improve glycaemic control and reduce progression to diabetes

https://doi.org/10.1136/ebn.12.2.45

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    S Czernichow

    Dr S Czernichow, Unite de Recherche en Nutrition Humaine, Bobigny, France; s.czernichow@uren.smbh.univ-paris13.fr

    QUESTION

    How do weight-reducing agents affect glycaemic parameters and risk of type 2 diabetes in predisposed individuals?

    REVIEW SCOPE

    Included studies were randomised, double-blind, placebo controlled trials (RCTs) that evaluated the effects of weight-reducing agents (eg, orlistat, sibutramine, and rimonabant) on fasting glucose or glycated haemoglobin (HbA1c) concentrations and had a duration of ⩾1 year. Studies of mixed populations were excluded. Outcomes included weight loss, fasting glucose and HbA1c concentrations, and diabetes.

    REVIEW METHODS

    Medline was searched from …

    View Full Text

    Footnotes

    • Source of funding: no external funding.